Previous Close | 2.6650 |
Open | 2.6700 |
Bid | 2.5400 x 100 |
Ask | 2.6500 x 100 |
Day's Range | 2.3501 - 2.6700 |
52 Week Range | 0.9700 - 4.0000 |
Volume | |
Avg. Volume | 302,261 |
Market Cap | 177.917M |
Beta (5Y Monthly) | 0.87 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2900 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.33 |
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA, from May 17-22. The presentation will take place on May 19th.
Trevi Therapeutics (TRVI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will attend and participate in the following events in April.